Head trauma and in vivo measures of amyloid and neurodegeneration in a population-based study
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received June 27, 2013
- Accepted in final form September 18, 2013
- First Published December 26, 2013.
Article Versions
- Previous version (December 26, 2013 - 13:00).
- You are viewing the most recent version of this article.
Author Disclosures
- Michelle M. Mielke, PhD,
- Rodolfo Savica, MD,
- Heather J. Wiste, BA,
- Stephen D. Weigand, MS,
- Prashanthi Vemuri, PhD,
- David S. Knopman, MD,
- Val J. Lowe, MD,
- Rosebud O. Roberts, MB, ChB, MS,
- Mary M. Machulda, PhD,
- Yonas E. Geda, MD,
- Ronald C. Petersen, MD, PhD and
- Clifford R. Jack Jr, MD
- Michelle M. Mielke, PhD,
NONE
NONE
I have received speaker honoraria from Eli Lilly.
Alzheimer's and Dementia: The Journal of the Alzheimer Association, associate editor, 2012-present Journal of Alzheimer Disease, associate editor, 2012-present
NONE
NONE
NONE
Eli Lilly
NONE
NONE
NONE
NONE
Dr. Mielke was funded by the following NIH grants: U01 AG037526, role: PI, Date: 08/15/2010-06/30/2015; R21 NS06027-01, role: PI, Date: 07/15/07-06/30/09; R21 AG028754, role: PI, Date: 09/01/07-08/31/09' R01 AG21136, role: Investigator, Date: 9/01/02-8/31/08
NONE
Dr. Mielke also received research support from the George and Cynthia Mitchell Foundation. Role: co-PI, Date: 07/01/2007-06/30/2010 and Walter S. and Lucienne B. Driskill Foundation which started in May 2012. Alzheimer drug discovery foundation. Role:PI. Date: 03/01/2013-present
NONE
NONE
NONE
NONE
NONE
NONE
- Rodolfo Savica, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Heather J. Wiste, BA,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Stephen D. Weigand, MS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Prashanthi Vemuri, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David S. Knopman, MD,
Lilly Pharmaceuticals, Data Safety Monitoring Board, ended 8/22/12; TauRx consultant 2012; Consultant, McGill University Alzheimer Program 9/19/12; Consultant Bluefield project (frontotemporal demantia) 2013; Lundbeck Pharmaceuticals (Sept 2013 ongoing)
NONE
(1) Lecture, University of Toronto, March 2012 (2) Lecture, University of Pennsylvania, January 2013 (3) Lecture, St Johns Hospital, Jackson Hole Wyoming June 2013 (4) Lecture, Amer Soc Neuroradiol, San Diego CA, May 2013
Neurology, Deputy Editor
NONE
NONE
NONE
(1) Janssen Alzheimer Immunotherapy program 3/29/11: honorarium paid to my institution; (2) Merck Alzheimer program 11/5/11 paid to my institution. (3) TauRx: two presentations in clinical trial investigator meetings.
NONE
NONE
NONE
(1) Janssen for Alzheimer clinical trial, (2) Baxter Laboratories for Alzheimer Clinical trial
NIH: R01-AG11378 ongoing, P50-AG 16574 (Mayo Alzheimer�s Disease Research Center) ongoing, U01 AG 06786 (Mayo Alzheimer Disease Patient Registry) ongoing. NIH R01 AG32306 FTD Neuro-imaging;Initiative. 1U01HL096917-01 ARIC Dementia Study.AG 037551 Chronic Kidney Disease and Cognitive functioning.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Val J. Lowe, MD,
(1) Bayer Pharmaceuticals
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) GE Health Care (2) Siemens Molecular Imaging (3) AVID Radiopharmaceuticals
(1) NIA R01 DC010367-01, CoI, 12/01/09-11/30/14 (2) NIA P50 AG016574-12, Co-PI Project #1, 05/01/09-04/30/14 (3) NIA R01 AG011378-16, CoI, 06/01/08-05/31/13 (4) NCI R01 CA136526-02, CoI, 01/01/09-11/30/14 (5) P30 CA015083-35, Program Director, 07/01/09-06/30/12 (6) P50 CA102701-07, CoI, 09/01/08-08/31/13 (7) R01 CA125614-04 , CoI,09/26/06-07/31/11 (8)R21 CA123909-02, CoI, 07/01/07-08/01/12
NONE
(1)MN Partnership for Biotechnology and Medical Genomics, PI, 01/01/09-12/31/13
NONE
NONE
NONE
NONE
NONE
NONE
- Rosebud O. Roberts, MB, ChB, MS,
NONE
NONE
NONE
I serve as an Associate Editor for Journal of Alzheimer's Disease.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
AbbVie Health Economics and Outcomes Research [coinvestigator]
NIH U01 AG006786 [Coinvestigator]
NONE
Mayo Clinic [coinvestigator], Driskill Foundation, and GHR Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Mary M. Machulda, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) National Institutes of Health; R01 DC 010367; Co-investigator 02/2010 - 01/2015 (2) Alzheimer's Association New Investigator Research Grant Co-Investigator 11/1/2012 - 10/31/2014 (3) National Institutes of Health; R01 DC 12519-01A1; Co-investigator 07/2013 - 06/2018
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Yonas E. Geda, MD,
NONE
NONE
NONE
2013 to present : Member, editoiral board of Psychogeriatrics.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
National Institutes of Health (NIH), K01 MH068531
NONE
1-Harold Amos Medical Faculty Development Award (RWJ foundation). 2- European Union Regional Development Fund (CZ.1.05/1.1.00/02.0123)
NONE
NONE
NONE
NONE
NONE
NONE
- Ronald C. Petersen, MD, PhD and
(1) Pfizer, Inc., Chair, Data Monitoring Committee ; (2) Janssen Alzheimer Immunotherapy, Chair, Data Monitoring Committee
NONE
NONE
NONE
NONE
Mild Cognitive Impairment,Oxford University Press, 2003
NONE
(1) GE Healthcare
NONE
NONE
NONE
NONE
National Institute on Aging: U01-AG006786 (PI) (1986-present) P50-AG016574 (PI) (1990-present) R01-AG011378 (Co-I) U01-AG024904 (Co-I)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Clifford R. Jack Jr, MD
scientific advisory panels: Siemens
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Allon and Baxter, perform MRI related services for clinical trial
RO1 AG011378 PI; U01 AG024904-01 co-I; RO1 AG37551 co-I; 1U01HL096917 co-I; U01 AG032438 co-I; RO1 AG041851-01 co-PI
NONE
NONE
Johnson and Johnson
NONE
NONE
NONE
NONE
NONE
- From the Divisions of Epidemiology (M.M.Mielke, R.O.R., R.C.P., Y.E.G.) and Biomedical Statistics and Informatics (H.J.W., S.D.W.), Department of Health Sciences Research; Departments of Neurology (R.S., D.S.K., R.O.R, R.C.P.), Psychiatry and Psychology (M.M.Machulda), and Radiology (P.V., V.J.L, C.R.J.), Mayo Clinic, Rochester, MN; and Departments of Psychiatry, Psychology, and Neurology (Y.E.G.), Mayo Clinic, Scottsdale, AZ.
- Correspondence to Dr. Mielke: mielke.michelle{at}mayo.edu
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Jeffrey Allen and Dr. Nicholas Purcell
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Article
Objective subtle cognitive difficulties predict future amyloid accumulation and neurodegenerationKelsey R. Thomas, Katherine J. Bangen, Alexandra J. Weigand et al.Neurology, December 30, 2019 -
Article
Amyloid deposition and brain structure as long-term predictors of MCI, dementia, and mortalityOscar L. Lopez, James T. Becker, YueFang Chang et al.Neurology, April 25, 2018 -
Article
Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adultsTengfei Guo, Susan M. Landau, William J. Jagust et al.Neurology, March 18, 2020 -
Article
Amyloid PET Imaging in Self-Identified Non-Hispanic Black Participants of the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) StudyKacie D. Deters, Valerio Napolioni, Reisa A. Sperling et al.Neurology, February 10, 2021